
Variable	Disease–free survival			Distant metastasis-free survival			Loco-regional relapse-free survival			Overall survival		
	HR	CI (%)	Р	HR	CI (%)	Р	HR	CI (%)	Р	HR	CI (%)	P
Sex												
Female	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
Male	1.13	0.74-1.71	0.573	1.77	0.90-3.49	0.098	1.87	0.92-3.81	0.084	1.08	0.63–1.87	0.77
Age												
≤45	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
>45	1.02	0.72-1.45	0.923	0.75	0.45-1.25	0.271	1.37	0.82-2.30	0.227	2.22	1.36-3.61	0.00
KPS												
70–80	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
90–100	0.41	0.15-1.09	0.073	0.26	0.08-0.84	0.024	0.74	0.10-5.37	0.769	0.29	0.09-0.91	0.03
T classification												
T1–2	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
Т3	0.91.	0.53-1.56	0.727	0.58	0.29–1.19	0.137	1.07	0.48-2.38	0.873	0.62.	0.33-1.19	0.14
T4	1.47	0.80-2.71	0.214	1.54	0.71-3.30	0.273	1.31	0.51-3.38	0.578	1.34	0.65-2.76	0.42
N classification												
N0-1	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
N2-3	1.24	0.87-1.76	0.238	1.97	1.18-3.26	0.009	1.29	0.77-2.15	0.340	1.68	1.05-2.67	0.03
Clinical stage												
III	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
IV	1.61	1.10-2.37	0.015	2.81	1.69–4.67	<0.001	1.00	0.53-1.89	0.999	2.25	1.39–3.64	0.00
Treatment												
Triweekly	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
Weekly	0.68	0.43-1.06	0.085	0.44	0.21-0.92	0.029	0.99	0.55-1.78	0.962	1.04	0.61-1.75	0.89

Supplementary Table 1 Univariate analysis in the unmatched group



Supplementary Figure 1: Compliance of concurrent cisplatin chemotherapy in the well-balanced cohort. (A) Weekly regimen. (B) Triweekly regimen.